Wedbush analyst Robert Driscoll has reiterated an 'Outperform' rating on Kura Oncology (KURA) and increased its price target from $36 to $38. This analyst action suggests continued confidence in the company's prospects, potentially leading to a positive, albeit moderate, short-term market reaction for KURA shares.
Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating for Kura Oncology and raised the price target from $36 to $38. This action signals a positive outlook from a prominent investment bank, suggesting that Wedbush sees continued upside potential for Kura Oncology's stock. This could lead to a short-term positive sentiment boost for KURA, as investors often react to analyst upgrades and price target increases. The long-term implications depend on Kura Oncology's actual performance and pipeline developments, but this analyst action provides a positive signal for current and potential investors. A key opportunity for traders is to capitalize on any immediate upward movement in KURA's stock price following this news.